Cargando…
Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry
Despite the withdrawal of the HeartWare Ventricular Assist Device (HVAD), hundreds of patients are still supported with this continuous-flow pump, and the long-term management of these patients is still under debate. This study aims to analyse 5 years survival and freedom from major adverse events i...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505657/ https://www.ncbi.nlm.nih.gov/pubmed/37727385 http://dx.doi.org/10.3389/ti.2023.11675 |
_version_ | 1785106949087428608 |
---|---|
author | Francica, Alessandra Loforte, Antonio Attisani, Matteo Maiani, Massimo Iacovoni, Attilio Nisi, Teodora Comisso, Marina Terzi, Amedeo De Bonis, Michele Vendramin, Igor Boffini, Massimo Musumeci, Francesco Luciani, Giovanni Battista Rinaldi, Mauro Pacini, Davide Onorati, Francesco |
author_facet | Francica, Alessandra Loforte, Antonio Attisani, Matteo Maiani, Massimo Iacovoni, Attilio Nisi, Teodora Comisso, Marina Terzi, Amedeo De Bonis, Michele Vendramin, Igor Boffini, Massimo Musumeci, Francesco Luciani, Giovanni Battista Rinaldi, Mauro Pacini, Davide Onorati, Francesco |
author_sort | Francica, Alessandra |
collection | PubMed |
description | Despite the withdrawal of the HeartWare Ventricular Assist Device (HVAD), hundreds of patients are still supported with this continuous-flow pump, and the long-term management of these patients is still under debate. This study aims to analyse 5 years survival and freedom from major adverse events in patients supported by HVAD and HeartMate3 (HM3). From 2010 to 2022, the MIRAMACS Italian Registry enrolled all-comer patients receiving a LVAD support at seven Cardiac Surgery Centres. Out of 447 LVAD implantation, 214 (47.9%) received HM3 and 233 (52.1%) received HVAD. Cox-regression analysis adjusted for major confounders showed an increased risk for mortality (HR 1.5 [1.2–1.9]; p = 0.031), for both ischemic stroke (HR 2.08 [1.06–4.08]; p = 0.033) and haemorrhagic stroke (HR 2.6 [1.3–4.9]; p = 0.005), and for pump thrombosis (HR 25.7 [3.5–188.9]; p < 0.001) in HVAD patients. The propensity-score matching analysis (130 pairs of HVAD vs. HM3) confirmed a significantly lower 5 years survival (41.7% vs. 64.1%; p 0.02), freedom from haemorrhagic stroke (90.5% vs. 70.1%; p < 0.001) and from pump thrombosis (98.5% vs. 74.7%; p < 0.001) in HVAD cohort. Although similar perioperative outcome, patients implanted with HVAD developed a higher risk for mortality, haemorrhagic stroke and thrombosis during 5 years of follow-up compared to HM3 patients. |
format | Online Article Text |
id | pubmed-10505657 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105056572023-09-19 Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry Francica, Alessandra Loforte, Antonio Attisani, Matteo Maiani, Massimo Iacovoni, Attilio Nisi, Teodora Comisso, Marina Terzi, Amedeo De Bonis, Michele Vendramin, Igor Boffini, Massimo Musumeci, Francesco Luciani, Giovanni Battista Rinaldi, Mauro Pacini, Davide Onorati, Francesco Transpl Int Health Archive Despite the withdrawal of the HeartWare Ventricular Assist Device (HVAD), hundreds of patients are still supported with this continuous-flow pump, and the long-term management of these patients is still under debate. This study aims to analyse 5 years survival and freedom from major adverse events in patients supported by HVAD and HeartMate3 (HM3). From 2010 to 2022, the MIRAMACS Italian Registry enrolled all-comer patients receiving a LVAD support at seven Cardiac Surgery Centres. Out of 447 LVAD implantation, 214 (47.9%) received HM3 and 233 (52.1%) received HVAD. Cox-regression analysis adjusted for major confounders showed an increased risk for mortality (HR 1.5 [1.2–1.9]; p = 0.031), for both ischemic stroke (HR 2.08 [1.06–4.08]; p = 0.033) and haemorrhagic stroke (HR 2.6 [1.3–4.9]; p = 0.005), and for pump thrombosis (HR 25.7 [3.5–188.9]; p < 0.001) in HVAD patients. The propensity-score matching analysis (130 pairs of HVAD vs. HM3) confirmed a significantly lower 5 years survival (41.7% vs. 64.1%; p 0.02), freedom from haemorrhagic stroke (90.5% vs. 70.1%; p < 0.001) and from pump thrombosis (98.5% vs. 74.7%; p < 0.001) in HVAD cohort. Although similar perioperative outcome, patients implanted with HVAD developed a higher risk for mortality, haemorrhagic stroke and thrombosis during 5 years of follow-up compared to HM3 patients. Frontiers Media S.A. 2023-09-04 /pmc/articles/PMC10505657/ /pubmed/37727385 http://dx.doi.org/10.3389/ti.2023.11675 Text en Copyright © 2023 Francica, Loforte, Attisani, Maiani, Iacovoni, Nisi, Comisso, Terzi, De Bonis, Vendramin, Boffini, Musumeci, Luciani, Rinaldi, Pacini and Onorati. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Health Archive Francica, Alessandra Loforte, Antonio Attisani, Matteo Maiani, Massimo Iacovoni, Attilio Nisi, Teodora Comisso, Marina Terzi, Amedeo De Bonis, Michele Vendramin, Igor Boffini, Massimo Musumeci, Francesco Luciani, Giovanni Battista Rinaldi, Mauro Pacini, Davide Onorati, Francesco Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry |
title | Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry |
title_full | Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry |
title_fullStr | Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry |
title_full_unstemmed | Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry |
title_short | Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry |
title_sort | five-year outcome after continuous flow lvad with full-magnetic (heartmate 3) versus hybrid levitation system (heartware): a propensity-score matched study from an all-comers multicentre registry |
topic | Health Archive |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505657/ https://www.ncbi.nlm.nih.gov/pubmed/37727385 http://dx.doi.org/10.3389/ti.2023.11675 |
work_keys_str_mv | AT francicaalessandra fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry AT loforteantonio fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry AT attisanimatteo fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry AT maianimassimo fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry AT iacovoniattilio fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry AT nisiteodora fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry AT comissomarina fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry AT terziamedeo fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry AT debonismichele fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry AT vendraminigor fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry AT boffinimassimo fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry AT musumecifrancesco fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry AT lucianigiovannibattista fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry AT rinaldimauro fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry AT pacinidavide fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry AT onoratifrancesco fiveyearoutcomeaftercontinuousflowlvadwithfullmagneticheartmate3versushybridlevitationsystemheartwareapropensityscorematchedstudyfromanallcomersmulticentreregistry |